Consensus statement regarding storage and reuse of previously reconstituted neuromodulators

Dermatol Surg. 2015 Mar;41(3):321-6. doi: 10.1097/DSS.0000000000000303.

Abstract

Background: Legacy recommendations suggest that vials of botulinum toxin be used within 24 hours of reconstitution and in a single patient. Current standard of care is consistent with storage after reconstitution and use of a single vial for several patients.

Objective: To develop expert consensus regarding the effectiveness and safety of storage and reuse of botulinum toxin.

Materials and methods: The American Society for Dermatologic Surgery authorized a task force of content experts to review the literature and provide guidance. Data extraction was followed by clinical question review, a consensus Delphi process, and validation of the results by peer review.

Results: After 2 rounds of Delphi process, the task force concluded by unanimous consensus and with the highest level of confidence that a vial of toxin reconstituted appropriately can, for facial muscle indications, be (1) refrigerated or refrozen for at least 4 weeks before injection without significant risk for contamination or decreased effectiveness and (2) used to treat multiple patients, assuming appropriate handling.

Conclusion: The standard of care, which allows for use of botulinum toxin more than 24 hours after reconstitution and in more than 1 patient per vial, is appropriate and consistent with the safe and effective practice of medicine.

Publication types

  • Review

MeSH terms

  • Adult
  • Botulinum Toxins, Type A / pharmacology*
  • Consensus
  • Drug Contamination
  • Drug Storage / standards
  • Humans
  • Neuromuscular Agents / pharmacology*
  • Practice Guidelines as Topic
  • Preservation, Biological / standards
  • Standard of Care
  • Time Factors

Substances

  • Neuromuscular Agents
  • Botulinum Toxins, Type A